MiReven, Silence Therapeutics plc Ink Collaboration
8/22/2012 11:00:58 AM
More...
|
Silence Therapeutics plc - Admission of Shares and Board Update
8/2/2012 1:10:23 PM
More...
|
Silence Therapeutics plc Announces Safe and Effective Dose Successfully Identified in Phase I Study of Atu027 and Potential Fund Raising
6/6/2012 11:01:30 AM
More...
|
New Data from Silence Therapeutics plc's Atu027 Anticancer Trial Published at American Society of Clinical Oncology
5/17/2012 10:47:40 AM
More...
|
Silence Therapeutics plc' Partner, Quark Pharmaceuticals Inc., Extends its Agreement With Pfizer Inc. (PFE) to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication
5/3/2012 7:02:19 AM
More...
|
Silence Therapeutics plc: Unaudited Preliminary Results for the Year Ended 31 December 2011
3/21/2012 10:27:17 AM
More...
|
Silence Therapeutics plc Forms Scientific Advisory Board and Forms Two New Research Collaborations to Further Strengthen Liver Pipeline
3/21/2012 10:22:34 AM
More...
|
Silence Therapeutics plc and Other Opponents of Tuschl I Patent Succeed in Limiting Scope and Ambiguity in the Patent
3/9/2012 10:11:05 AM
More...
|
Silence Therapeutics plc Announces Board Changes and Appointment of New Chief Executive Officer
2/10/2012 6:33:23 AM
More...
|
Silence Therapeutics plc Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics
1/9/2012 10:34:16 AM
More...
|
|